Pricing Log in Create free account
Sunday 18 October 2026 Export MCRB’s income statement to Excel — free account

Seres Therapeutics, Inc.

MCRB Healthcare Biotechnology

In the quarter to June 2026, revenue grew 96.8%, EPS grew 120.7% and free cash flow fell 66.2%, each against the same quarter a year earlier.

2.46 0.07 −2.77%
Market cap
$25.2M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
n/a
Altman Z
−10.99
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 4 — — 4 — — 4 — — 4 — —
Insider Ownership 22.32%

Capital & Financial Ratios $m

Market Cap 25.15
Revenue 1.88
Net Income (22.46)
Free Cash Flow (51.25)
Net Debt (15.59)
Current Ratio 2.11 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.72) (negative: loss-making)
P/S ratio 12.68 (above 10: high)
P/B ratio 0.69
Past 5Y EPS Growth —
This Y EPS Growth (649.09%) (below 0%: weak)
Next Y EPS Growth (40.71%) (below 0%: weak)
Next Y revenue growth 1,649.05% (at or above 10%: strong)
Next 5Y EPS Growth 25.41% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 58.8×, against a ten-year median of 6.2×; over the ten years it ranged from 0.5× in 2023 to 129× in 2023.
P/S against its own 10 years 60.79%
10-year low 10-year high
P/B against its own 10 years 0.11%
10-year low 10-year high
EV/Sales against its own 10 years 82.41%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 128 31 46 16
Receivables 9 2 1 25
Inventory — — — —
Other — — — —
175 39 49 42
2023 2024 2025 Q'26
Payables 4 4 2 1
ST’ Debt — — — —
Other — — — —
99 41 19 20

Compound Annual Growth %

10y 5y 3y
Sales — (53.03%) (82.41%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (14.24%) (24.03%) 60.06%

Revenue $m

Mar Jun Sep Dec Year
’26 0 1 — — —
’25 — — 0 0 1
’23 (1) 126 0 0 126
’22 1 1 3 1 7
’21 6 5 127 7 145
’20 8 6 1 18 33
’19 7 13 7 8 35
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (22) — — —
’25 27 (13) 2 (15) 1
’24 (35) (40) (35) (39) (149)
’23 (77) 66 (59) (47) (117)
’22 (66) (50) (60) (53) (229)
’21 (29) (40) 128 (52) 7
’20 (24) (26) (26) (18) (94)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (22) — — —
’25 27 (13) 2 (15) 1
’24 (35) (40) (35) (39) (149)
’23 (81) 65 (61) (48) (125)
’22 (69) (52) (61) (56) (239)
’21 (31) (42) 124 (53) (3)
’20 (24) (26) (26) (18) (94)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.08) 0.47 — — —
’25 3.75 (2.27) 0.94 (1.76) 0.64
’24 (5.40) (4.40) 11.60 (1.78) 0.00
’23 (11.40) 7.20 (7.40) (6.40) (17.80)
’22 (12.20) (14.00) (9.80) (10.80) (46.20)
’21 (7.80) (10.60) 14.40 (11.00) (14.40)
’20 (5.60) (5.60) (7.20) (3.60) (22.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 161.00 177.00 90.40 40.40 50.40 108.20 50.00 18.20 10.80 6.53

Analyst estimates 2026–2028

Powerpack
High 719.60 348.40 226.90 167.80 770.00 598.00 189.80 137.40 41.00 29.98
People
People Employees 127 138 145 108 155 333 431 160 103 66
Revenue/emp, $m 0.17 0.23 0.19 0.32 0.21 0.44 0.02 0.79 0.00 0.01
Income, $m
Income, $m Revenue 22 32 28 35 33 145 7 126 — 1
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00
EBT (92) (89) (99) (70) (89) (66) (184) (190) (126) 6
EBT margin, % (420.74) (278.44) (350.03) (203.68) (268.33) (45.25) (2,575.49) (150.51) 0.00 721.93
Net income (92) (89) (99) (70) (89) (66) (250) (114) 0 6
Depreciation 4 7 8 8 8 9 8 7 7 4
Per share, $
Per share, $ Revenue 10.92 15.87 13.88 12.18 8.33 31.61 1.32 19.74 0.00 0.09
Earnings (46.00) (44.20) (48.60) (24.80) (22.40) (14.40) (46.20) (17.80) 0.00 0.64
Cash flow 22.04 (37.34) (30.85) (27.01) (23.46) 1.46 (42.34) (18.34) (19.13) 0.13
Capex (10.79) (2.31) (0.95) (0.35) (0.15) (2.09) (1.82) (1.25) (0.05) 0.00
Free cash flow 11.26 (39.65) (31.80) (27.37) (23.61) (0.63) (44.16) (19.58) (19.17) 0.12
Book value 66.57 30.01 (23.58) (17.06) 43.80 28.68 2.00 (7.01) 1.77 4.99
Shares, m 2 2 2 3 4 5 5 6 8 9
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 22.21
P/S 18.33 13.29 6.52 5.66 58.85 5.27 81.88 1.42 — 89.49
P/B 3.01 7.03 0.00 0.00 11.19 5.81 54.12 0.00 — 2.98
EV/Sales 9.94 8.90 3.72 3.63 51.96 3.44 63.53 1.21 — 128.00
EV/FCF 9.65 (3.56) (1.62) (1.62) (18.32) (172.98) (1.90) (1.22) — 175.40
Cash, $m
Cash, $m Operating cash flow 44 (76) (63) (77) (94) 7 (229) (117) (149) 1
Capex (21) (5) (2) (1) (1) (10) (10) (8) 0 0
Free cash flow 22 (80) (65) (78) (94) (3) (239) (125) (149) 1
Balance, $m
Balance, $m Working capital 168 123 51 54 222 221 109 77 (3) 30
Total debt 11 9 7 25 25 25 51 102 — —
Net debt (183) (141) (79) (70) (229) (266) (131) (26) (31) (46)
Shareholders’ equity 133 61 (48) (48) 175 132 11 (45) 14 44
Returns, %
Returns, % ROA (37.41) (38.68) (63.83) (55.58) (37.50) (18.80) (71.10) (32.15) 0.05 4.10
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (54.18) (92.46) (1,563.81) 145.85 (140.99) (42.83) (351.62) 667.53 (0.88) 19.64
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Seres Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IBO Impact Biomedical Inc. $27.0M 0.2× — −57.14% (below 0%: shrinking) n/m +167.72% (above 0%: growing) 66.67% (23,400.00%) Compare
ATOS Atossa Therapeutics, Inc. $26.4M — (loss-making) — −94.28% (below 0%: shrinking) n/m −32.86% (below 0%: shrinking) 0.00% 0.00% Compare
IGC IGC Pharma, Inc. $26.3M — (loss-making) — (loss-making) −19.70% (below 0%: shrinking) n/m −103.33% (below 0%: shrinking) 18.11% (1,050.57%) Compare
MCRB Seres Therapeutics, Inc. $25.2M — (loss-making) — (loss-making) +96.79% (above 0%: growing) n/m −66.15% (below 0%: shrinking) 100.00% (2,890.35%)
ABVC ABVC BioPharma, Inc. $24.9M — (loss-making) — (loss-making) +66,233.33% (above 0%: growing) n/m +72.66% (above 0%: growing) 100.00% 0.00% Compare
BYSI BeyondSpring Inc. $23.9M — (loss-making) — (loss-making) +87.78% (above 0%: growing) n/m +35.78% (above 0%: growing) 100.00% 0.00% Compare
CYAD Celyad SA $23.8M — (loss-making) — (loss-making) — n/m +78.72% (above 0%: growing) 0.00% 0.00% Compare
PLRZ Polyrizon Ltd. $23.7M — — — — −744.51% (below 0%: shrinking) — — Compare
IMMP Prima BioMed Ltd $23.7M — (loss-making) — — n/m −589,653.13% (below 0%: shrinking) 100.00% (101.89%) Compare
Median of peers $24.4M — — −19.70% — +1.46% 66.67% 0.00%

All 614 Biotechnology stocks →

Seres Therapeutics, Inc. (MCRB) key facts

  • Seres Therapeutics, Inc. (MCRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MCRB traded at $2.46, a market capitalization of $25.2 million.
  • Return on equity was 19.6% and debt-to-equity 0.00.
  • Its Altman Z-score is −10.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Seres Therapeutics, Inc. (MCRB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MCRB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com